Benefit of ADP receptor antagonists in atherothrombotic patients: New evidence

Cerebrovascular Diseases

Volumn 11, Issue SUPPL. 2, 2001, Pages 5-10

  Bogousslavsky, Julien ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Atherothrombosis; Clopidogrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ATHEROSCLEROSIS; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STROKE; THROMBOSIS; VASCULAR DISEASE;

ARTERIOSCLEROSIS; ASPIRIN; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, PURINERGIC P2; THROMBOSIS; TICLOPIDINE;

EID: 0035060668     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049138     Document Type: Conference Paper

References (28)

1. Antiplatelet therapy
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
3. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
4. Relationship of cardiac disease to stroke occurrence, recurrence and mortality
5. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > 62 years of age
6. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
7. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel compared with aspirin
8. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus
9. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis
10. The benefit of clopidogrel over aspirin is amplified in high-risk subgroups with a prior history of ischaemic events
11. Use of concomitant medications in the CAPRIE trial: Clopidogrel is unlikely to be associated with clinically significant drug interactions
12. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
13. Warfarin anticoagulation and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial
14. Evidence for a potential adverse interaction between aspirin and angiotensin converting enzyme inhibitors after percutaneous coronary angioplasty: The EPILOG trial
15. Concomitant use of ACE inhibitors and antiplatelet therapies: Clopidogrel versus aspirin
16. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril
17. Warfarin and antiplatelet therapy study in chronic heart failure (WATCH): Trial design
18. Comparative gastrointestinal tolerability of clopidogrel and aspirin: Results from the CAPRIE trial
19. Gastrointestinal bleeding with clopidogrel compared with aspirin
20. Gastroduodenal tolerance of clopidogrel 75 mg versus aspirin 325 mg in healthy volunteers: A gastroscopic study
21. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
22. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis
23. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
24. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
25. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet in unplanned and elective coronary stenting: The Full Anticoagulation versus Aspirin plus Ticlopidine (FANTASTIC) study
26. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
27. A clinical trial comparing three antithrombotic-drug regimes after coronary-artery stenting
28. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)